Latest News

(UroToday.com) Clinical stage 1 testicular cancer is managed surgically, with cancer-specific survival rates approaching 100%. Risk factors for recurrence vary by histology and include the size of the tumor (seminoma) and presence of lymphovascular invasion and degree of embryonal carcinoma predominance (non-seminoma). In this poster, Dr. Rohit Badia and colleagues investigated the utility of pre-orchiectomy serum […]

(UroToday.com) An ongoing debate in the field of advanced renal cell carcinoma is the benefit and patient selection for cytoreductive nephrectomy. In an analysis presented last year at the 2020 GU ASCO symposium, Dr. Ashanda Esdaille and colleagues presented data on overall survival in 1100+ patients who underwent upfront cytoreductive nephrectomy at 5 tertiary care centers […]

(UroToday.com) The combination chemotherapy regimen of paclitaxel, ifosfamide, and cisplatin (TIP) for four cycles was published as a regimen for favorable risk progressive metastatic germ cell tumors in 20051 based on a 46-patient study with 70% achieving a complete response and a 2-year progression-free survival rate of 65%. Favorable risk was classified as only one prior […]

(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Angela Smith discussing deintensification of management of low-risk non-muscle-invasive bladder cancer. Dr. Smith notes that it is important to distinguish between low risk versus low grade non-muscle-invasive bladder cancer. According […]

(UroToday.com) Industrial byproducts and environmental pollutants are associated with the development of urothelial carcinoma. While tobacco exposure (50-65%) is the major risk factor for urothelial carcinoma, the interaction between sources of industrial byproducts and environmental pollutants and incidence of urothelial carcinoma in surrounding communities has been infrequently explored. At the American Society of Clinical Oncology Genitourinary Cancers […]

(UroToday.com) There are several PD-1 immune-checkpoint inhibitors including nivolumab that are approved in urothelial cancer. Recently, in the front-line setting, improved activity of combined PD-L1 and CTLA4 immune-checkpoint inhibition has been reported and a phase III trial with nivolumab plus ipilimumab is ongoing. At the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU),  Dr. Marc-Oliver Grimm […]

(UroToday.com) Chemotherapy or radiotherapy are standard treatments for stage II seminoma, though they are associated with significant long-term treatment-related toxicities. Long-term morbidity from chemotherapy and radiotherapy is real, as these are young patients with excellent cure rates thus potentiating cumulative toxicities. These toxicities may include cardiac events, secondary cancers (hematologic and solid tumors), metabolic syndrome, […]

(UroToday.com) There has been a rapid evolution in treatment options for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) since the spring of 2018. Up until the presentation of SPARTAN and PROSPER trials, reporting on the use of apalutamide and enzalutamide in non-metastatic castration-resistant prostate cancer, at GU ASCO in February 2018, there were no specifically approved […]

(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), included a presentation from Dr. Eugene Pietzak discussing the molecular landscape of non-muscle-invasive bladder cancer. Dr. Pietzak notes that there are relatively well-established molecular subtypes for muscle-invasive bladder cancer, whereas subtypes in non-muscle-invasive bladder cancer […]

(UroToday.com) BCG-unresponsive non-muscle invasive bladder cancer remains a challenging disease to treat given the limited treatment options and a proportion of this patient population that are either unfit or unwilling to undergo radical cystectomy. Hyperthermic Intra-Vesical Chemotherapy (HIVEC) is a treatment option for these patients, which includes intravesical instillation of a chemotherapeutic agent with pre-treatment warming […]